According
to a new market report published by Transparency Market Research
“Antibacterial Drugs Market - Global Industry Analysis, Size,
Share, Growth, Trends and Forecast 2015 - 2023,” the global
antibacterial drugs market was valued at USD 43.9 billion in 2014 and
is estimated to reach USD 38.8 billion by 2023 at a CAGR of (1.3%)
from 2015 to 2023.
Antibacterial
drugs have been utilized by humans since the discovery of the first
antibiotic penicillin in 1928 by Alexander Fleming and has evolved
into a multi-billion dollar market. These drugs treat infectious
diseases caused by gram positive, gram negative, aerobic and
anaerobic bacteria that cannot be treated by any other method unlike
other diseases, where substitute methodologies are available. This
property has made antibacterial drugs an indispensable part of human
health care. Over the period, the bacteria have genetically mutated
giving rise to multi-drug resistant (MDR) variants. The prevalence of
MDR bacterial infections is also on a hike; according to World Health
Organization (WHO) in 2013, there were about 480 000 new cases of
multidrug-resistant tuberculosis (MDR-TB); extensively drug-resistant
tuberculosis (XDR-TB) has been identified in 100 countries. MDR-TB
requires treatment courses that are much longer and less effective
than those for non-resistant TB.
Browse
the Antibacterial Drugs Market Report at
http://www.transparencymarketresearch.com/antibacterial-drugs-market.html
Antibacterial
drugs are classified into eight major classes, namely,
aminoglycosides, B-Lactams, tetracyclines, sulfonamides, quinolones,
macrolides, phenicols and miscellaneous antibacterials. The B-lactams
class was the largest segment of the global antibacterial drugs
market in 2014, with 58% share. Quinolones was identified as the
second largest class, which held a share of 17% of the global
antibacterial drugs market in 2014 and is expected to report a
negative CAGR during the forecast period. This decline in revenue
will be primarily witnessed due to sales erosion from patent
expiries, evolution of resistant strains of bacteria and rising
concerns regarding tendon ruptures and tendon damage from
fluoroquinolones administration. However, the demand for macrolides
and quinolones/fluoroquinolones classes will remain high during the
forecast period, due to their usage in treating a large number of
infections coupled with expected launch of pipeline drugs in these
classes during the forecast period.
The
key drugs in pipeline have been identified for this market (currently
in phase III clinical trials) and sales forecast has been provided
for those expected to be launched during the forecast period (2015 to
2022). These include solithromycin (Cempra, Inc.), VivaGel (SPL7013)
(Starpharma Holdings Limited), surotomycin (Merck & Co.),
MK-3415A (Merck & Co.) and others. These drugs promise to provide
improved efficacy, shorter onset of action and fewer side effects as
compared to the currently available antibacterial drugs. Hence,
future commercialization of these drugs during the forecast period is
anticipated to have a profound impact on the growth of the overall
antibacterial drugs market.
AstraZeneca
plc, Bayer AG, Bristol-Myers Squibb Company, Eli Lilly and Company,
Forest Laboratories, Inc., GlaxoSmithKline plc, Johnson &
Johnson, Merck & Co., Inc., Novartis AG, Pfizer, Inc., and Sanofi
are the major players operating in the global antibacterial drugs
market. These players have worldwide presence in the pharmaceutical
industry and are involved in constant competition with each other.
Pfizer, Inc. was observed to be the leading player in the
antibacterial drugs market. Major end-users for antibacterial drugs
include hospitals, private clinics, physicians and patients.
Browse
the full Antibacterial Drugs Market (By Class- Aminoglycosides,
B-Lactams, Tetracyclines, Sulfonamides, Quinolones/ Fluoroquinolones,
Macrolides, Phenicols and Miscellaneous
Browse
the Press
Release:http://www.transparencymarketresearch.com/pressrelease/antibacterial-drugs-market.htm
The
global antibacterial drugs market has been segmented as below:
Global
Antibacterial Drugs Market, by Drug Class, 2013 – 2023 (USD
Million)
Aminoglycosides
B-Lactams
Tetracyclines
Sulfonamides
Quinolones/Fluoroquinolones
Macrolides
Phenicols
Miscellaneous
Antibacterials
Pipeline
Analysis of Antibacterial Drugs Market
Actoxumab/Aezlotoxumab,
(MK-3415A)
Surotomycin
(MK-4261)
Arikace
Cadazolid
Ciprofloxacin/Fluocinolone
Acetonide
Zempia
(E-101)
Carbavance
(meropenem/RPX7009)
Ozenoxacin
RHB-105
SPL7013
Delafloxacin
Solithromycin
(CEM-101)
Eravacycline
Delamanid
SYM-1219
Omadacycline
(PTK-0796)
Plazomycin
Global
Antibacterial Drugs Market, by Geography, 2013 – 2023 (USD Million)
North
America
U.S.
Canada
Europe
U.K.
Germany
Rest
of Europe
Asia-Pacific
China
Japan
Rest
of Asia Pacific
Latin
America
Brazil
Rest
of Latin America
Rest
of the World (RoW)
Request
a Brochure of this Report:
http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1567
About
Us
Transparency
Market Research is a global market intelligence company, providing
global business information reports and services. Our exclusive blend
of quantitative forecasting and trends analysis provides
forward-looking insight for thousands of decision makers. Our
experienced team of Analysts, Researchers, and Consultants, use
proprietary data sources and various tools and techniques to gather,
and analyze information.
Our
data repository is continuously updated and revised by a team of
research experts, so that it always reflects the latest trends and
information. With a broad research and analysis capability,
Transparency Market Research employs rigorous primary and secondary
research techniques in developing distinctive data sets and research
material for business reports.
Contact
Mr.
Nachiket Ghumare
90
State Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-618-1030
USA
- Canada Toll Free: 866-552-3453
Email:
sales@transparencymarketresearch.com
Website:
http://www.transparencymarketresearch.com/
No comments:
Post a Comment